European Medicines Agency Accepts Astellas' Marketing Authorization Application for Roxadustat

TOKYO and SAN FRANCISCO, May 20, 2020 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and FibroGen, Inc. (Nasdaq: FGEN, CEO: Enrique Conterno, "FibroGen") today announced the marketing authorization application (MAA) for roxadustat...

from PR Newswire: https://ift.tt/3e8raiS